About Galanin receptor type 2
Galanin receptor type 2 (GALR2) is a protein
from Homo sapiens identified by UniProt accession
O43603, 387 residues long.
MolForge cross-references it against 0 known binders and
106 disease associations.
Target properties
| Protein name | Galanin receptor type 2 |
| UniProt accession | O43603 |
| Gene | GALR2 |
| Organism | Homo sapiens |
| Length | 387 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (106)
Diseases linked to this target (Open Targets).
- head and neck squamous cell carcinoma · score 0.18
- breast adenocarcinoma · score 0.17
- neoplasm · score 0.10
- plasma fibronectin deficiency · score 0.07
- isolated asymptomatic elevation of creatine phosphokinase · score 0.06
- mononeuropathy · score 0.05
- colitis · score 0.05
- diabetic nephropathy · score 0.04
- Hereditary persistence of alpha-fetoprotein · score 0.04
- neutropenia, severe congenital, 2, autosomal dominant · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O43603-F1 | alphafold | PREDICTED | 77.93 | — |
Amino-acid sequence (387 residues)
MNVSGCPGAG NASQAGGGGG WHPEAVIVPL LFALIFLVGT VGNTLVLAVL LRGGQAVSTT NLFILNLGVA DLCFILCCVP FQATIYTLDG WVFGSLLCKA VHFLIFLTMH ASSFTLAAVS LDRYLAIRYP LHSRELRTPR NALAAIGLIW GLSLLFSGPY LSYYRQSQLA NLTVCHPAWS APRRRAMDIC TFVFSYLLPV LVLGLTYART LRYLWRAVDP VAAGSGARRA KRKVTRMILI VAALFCLCWM PHHALILCVW FGQFPLTRAT YALRILSHLV SYANSCVNPI VYALVSKHFR KGFRTICAGL LGRAPGRASG RVCAAARGTH SGSVLERESS DLLHMSEAAG ALRPCPGASQ PCILEPCPGP SWQGPKAGDS ILTVDVA
Explore Galanin receptor type 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets